Detalhe da pesquisa
1.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
2.
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Invest New Drugs
; 40(4): 762-772, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35467243
3.
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Haematologica
; 107(7): 1608-1618, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320785
4.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Blood
; 133(18): 1964-1976, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850381
5.
Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Br J Haematol
; 177(1): 72-79, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211579
6.
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Am J Hematol
; 92(11): 1156-1162, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28719025
7.
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Cancer
; 122(4): 559-64, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26565895
8.
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Br J Haematol
; 175(4): 631-640, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27469075
9.
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Blood
; 124(15): 2354-61, 2014 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25161267
10.
Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era.
Br J Haematol
; 168(5): 708-18, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25382108
11.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Am J Hematol
; 90(9): 778-83, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26044261
12.
MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Cancer
; 120(24): 3884-95, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25060588
13.
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Br J Haematol
; 165(6): 793-800, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24628515
14.
Brentuximab vedotin in patients with relapsed HIV-related lymphoma.
J Natl Compr Canc Netw
; 12(1): 16-9; quiz 19, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24453289
15.
Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.
J Natl Compr Canc Netw
; 12(4): 465-71, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24717566
16.
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
CPT Pharmacometrics Syst Pharmacol
; 13(1): 23-28, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37915242
17.
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Blood Adv
; 8(7): 1612-1620, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237077
18.
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Br J Haematol
; 181(2): 264-267, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419407
19.
Peripheral T-cell lymphoma: new therapeutic strategies.
Oncology (Williston Park)
; 27(9): 878-84, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24282984
20.
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
J Allergy Clin Immunol
; 140(3): 875-879.e1, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28389390